Phosphodiesterase 5 inhibitors for pulmonary hypertension
is a topic covered in the Evidence-Based Medicine Guidelines
To view the entire topic, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
"Phosphodiesterase 5 Inhibitors for Pulmonary Hypertension." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/451839/all/Sildenafil_for_pulmonary_hypertension.
Phosphodiesterase 5 inhibitors for pulmonary hypertension. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/451839/all/Sildenafil_for_pulmonary_hypertension. Accessed October 21, 2019.
Phosphodiesterase 5 inhibitors for pulmonary hypertension. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/451839/all/Sildenafil_for_pulmonary_hypertension
Phosphodiesterase 5 Inhibitors for Pulmonary Hypertension [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 October 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/451839/all/Sildenafil_for_pulmonary_hypertension.
TY - ELEC
T1 - Phosphodiesterase 5 inhibitors for pulmonary hypertension
ID - 451839
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451839/all/Sildenafil_for_pulmonary_hypertension
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine